Both in Pharmaceuticals
ARS Pharmaceuticals vs Emergent Biosolutions
Over the past year SPRY returned −62.3% and EBS returned −45.4%; their daily moves had a correlation of 0.21.
SPRY −62.3% EBS −45.4%Growth of $1, one year, split-adjusted
| Metric | SPRY | EBS |
|---|---|---|
| Price | $3.38 | $6.81 |
| Market cap | $336.1M | $349.2M |
| Today | −7.65% | −5.68% |
| 1 month | −18.0% | +6.9% |
| 6 months | −60.5% | −19.6% |
| Year to date | −71.0% | −44.9% |
| 1 year | −62.4% | −27.6% |
| Revenue growth (YoY) | +114.2% | +66.3% |
| Gross margin | 61.8% | 58.6% |
| Net margin | −185.2% | −76.9% |
| P/E (TTM) | — | — |
| Price / sales | 2.9× | 0.5× |
| Net cash | -$27.8M | -$442.1M |
| Dividend yield | — | — |
| Volatility (60d) | 71.5% | 67.4% |
| Short % of float | 40.5% | 19.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).